Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J5HR
|
|||
| Former ID |
DNCL002416
|
|||
| Drug Name |
LGK974
|
|||
| Synonyms |
1243244-14-5; LGK974; LGK-974; 2-(2',3-Dimethyl-[2,4'-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide; WNT-974; LGK 974; UNII-U27F40013Q; CHEBI:78030; CHEMBL3188386; U27F40013Q; AK165831; 2-(2',3-dimethyl-2,4'-bipyridin-5-yl)-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide; MLS006011002; SCHEMBL1723611; KS-00000SUI; MolPort-029-945-290; HMS3653G11; BCP08495; EX-A1402; ZINC95930187; STL556617; BDBM50133870; BBL102809; 2140AH; s7143; AKOS025211913; SB19314; CS-2807; DB12561; NCGC00347950-07; NCGC00347950-01; OR302651; QC-11701
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H20N6O
|
|||
| Canonical SMILES |
CC1=CC(=CN=C1C2=CC(=NC=C2)C)CC(=O)NC3=NC=C(C=C3)C4=NC=CN=C4
|
|||
| InChI |
1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)
|
|||
| InChIKey |
XXYGTCZJJLTAGH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1243244-14-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:78030
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein-serine O-palmitoleoyltransferase porcupine (PORCN) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.